BriaCell’s Bria-IMT shows high survival rate in Phase 2 breast cancer trial

BriaCell (BCTX) has reported updated survival data from its ongoing Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer, MBC. BriaCell’s most recent Phase 2 study cohort of 25 patients achieved a 52% one-year survival rate. 11 of these patients remain alive as of most recent contact, including one patient at 38.3 months and another at 30.3 months. Survival rate exceeds the survival expectations with the current standard of care therapies in similar patient populations. Many patients had very advanced metastatic breast cancer, having already failed multiple prior lines of therapy including check point inhibitors and antibody-drug conjugates such as Trodelvy – sacituzumab govitecan- and Enhertu. No treatment discontinuations attributed to Bria-IMT have been reported. BriaCell’s Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 were treated with the formulation currently being used in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer. Final median overall survival calculation for the Phase 2 study is pending for some sub populations as many patients remain alive. No Bria-IMT-related discontinuations have been reported to date.